ArticleMedicina (Kaunas, Lithuania)2021

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Shinsuke Suzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.